Top 8 Robotic Surgery Companies in the United States

Find out more about US Market Report Suite for Surgical Navigation and Robotic Systems *2024 update*

About Robotic Surgery

Surgery has progressed from a risky art into a sophisticated and ever-evolving scientific discipline capable of treating many diseases and conditions. Until the industrial revolution, surgeons struggled with three principal obstacles that plagued the medical profession from its infancy: bleeding, pain, and infection. Recent technological advances have increased the types of procedures that are able to be performed and, more importantly, revolutionized the way in which these procedures can be performed.

The field of robotic-assisted surgery is still in its primary stages, as many of these systems are expensive, bulky, and have not been widely accepted as better alternatives to traditional surgery. However, the current systems on the market and the systems being developed are changing the way that robotic systems are perceived by both surgeons and patients. Constituting around 600,000 robotic-assisted surgical procedures performed in the United States last year, the robotic surgery market is expected to grow impressively to approach 1 million procedures by 2028. Because of this, we wanted to highlight a few of the top robotic surgery companies in the U.S.

Key Developments in Surgical Robotics

Despite the challenges, the surgical robotics space is witnessing significant advancements and shifts. Leading companies continue to innovate, pushing the boundaries of what’s possible with robotic-assisted surgery. For instance, some are moving forward with next-generation robotic systems that promise increased precision and efficiency in soft-tissue procedures.

Other players are navigating the complex regulatory landscape, preparing to submit their advanced systems for investigational device exemptions, a crucial step towards initiating clinical trials. This process underscores the ongoing commitment to improving surgical outcomes through cutting-edge technology.

Industry Dynamics

While the potential for growth is substantial, the industry is not without its hurdles. Some companies have had to make difficult decisions, such as workforce reductions, in response to evolving market conditions. Meanwhile, others have scaled back or discontinued certain projects, reflecting the intense competition and high stakes involved in this field.

These developments illustrate the dynamic nature of the surgical robotics space, where innovation and adaptation are key to success. As these technologies continue to evolve, they hold the promise of transforming surgical practices and improving patient care worldwide.

Top Robotic Surgery Companies in the U.S.

Intuitive Surgical
PROCEPT BioRobotics
Stryker
Johnson & Johnson
Smith & Nephew
Medtronic
Accuray
Globus Medical

Intuitive Surgical

In 2023, Intuitive Surgical dominated the surgical robotics market. After receiving FDA approval for its first da Vinci® system in 2000, the company introduced several multi-port models, including the da VinciS® in 2006 and da Vinci Si® in 2009. However, the da Vinci Si® will be phased out by 2024. Intuitive’s flagship fourth-generation robot, the da Vinci Xi®, launched in 2014, followed by the FDA-cleared da Vinci X® in 2017, used for procedures like hysterectomy, prostatectomy, and hernia repair.

Intuitive’s influence extends far beyond its product lineup. As a pioneer in soft-tissue surgical robotics, the company has placed over 8,000 systems worldwide, executing more than 14 million procedures to date. Just last year alone, approximately 2.3 million procedures were completed using their systems, underscoring the global impact of their technology.

President Dave Rosa, a 27-year veteran of Intuitive, highlighted the company’s leadership and pioneering role in the industry. Promoted to president in 2023, Rosa shared insights on how competition within the growing field validates the dedication and innovation that Intuitive has invested. His remarks emphasized that the company’s advancements have not only expanded the reach of minimally invasive surgery but have also introduced superior alternatives to traditional methods like laparoscopy.

The entry of both large and small competitors into the market further confirms the value and potential of surgical robotics. These developments signify a broader validation of Intuitive’s contributions and the transformative impact they continue to have on the medical landscape.

PROCEPT BioRobotics

PROCEPT BioRobotics holds the second-leading position in the surgical robotics market, thanks to its presence in other MIS capital equipment segments. This U.S.-based company markets the AquaBeam® Robotic System, which enables robotic-assisted aquablation therapy to treat benign prostatic hyperplasia (BPH). The system received FDA clearance in December 2017 and is known for providing effective and safe outcomes for men with lower urinary tract symptoms (LUTS) caused by BPH, regardless of prostate size, shape, or surgeon experience.

Stryker

In 2023, Stryker ranked third in the surgical robotics market. The company entered the space by acquiring MAKO Surgical Corp. for $1.65 billion in 2013, rebranding its Rio® Robotic Arm as the Mako™ Robotic Arm. The Mako™ system is used for partial knee and total hip arthroplasty. In 2017, Stryker expanded its use to total knee arthroplasty, after receiving FDA approval in 2015 but opting for a controlled release until 2017.

Johnson & Johnson

In 2023, Johnson & Johnson ranked fourth in the surgical robotics market, driven by DePuy Synthes’ share in robotic-assisted orthopedic surgery. In January 2021, the company received FDA clearance for its VELYS™ Robotic-Assisted Solution, designed for use with the ATTUNE® Total Knee System. It also supports hip and shoulder procedures and was first used in Australia in December 2021. To enhance its orthopedic capabilities, DePuy Synthes acquired CUPTIMIZE™ Hip-Spine Analysis in March 2022 and partnered with Tinavi Medical Technologies in 2019 to promote robotic solutions in China for spine and trauma procedures.

Johnson & Johnson is making significant strides in advancing its Ottava surgical robot to compete with industry leader Intuitive. For years, they’ve kept details under wraps, but recently, they’ve opened up about their future plans. In late 2023, the company announced its intention to submit the Ottava system for FDA investigational device exemption (IDE) in the latter half of 2024. This will pave the way for clinical trials, marking a pivotal step in Ottava’s development journey.

The Ottava system is uniquely designed with four robotic arms integrated into a standard surgical table, a streamlined design compared to its earlier six-arm prototype. This configuration provides a seamless and compact setup, allowing the arms to be discreetly stowed when not in use. This flexibility facilitates a clutter-free surgical environment and supports efficient operations.

One of the standout features of the Ottava is its “twin motion” capability. This innovation ensures synchronized movement between the table and the robotic arms, enhancing surgical precision and adaptability. It allows medical teams to address critical needs, like repositioning patients, without halting the procedure.

In summary, Johnson & Johnson’s Ottava is focused on simplifying surgical processes and introducing new surgical experiences through its inventive architecture. This aligns with their goal to meet evolving clinical needs and set new standards for surgical robotics.

Smith & Nephew

In 2023, Smith & Nephew ranked second in the robotic-assisted orthopedic surgery market, placing fifth overall in the surgical robotics market. In 2015, the company acquired Blue Belt Technologies and its NAVIO™ platform for $275 million, which enabled robotic-assisted partial knee replacements. NAVIO™ is being phased out in favor of the next-generation CORI™ Surgical System, FDA-approved in 2020. CORI™ offers 29% faster resection, a quicker refresh rate, and greater efficiency, combining a compact handheld instrument with a navigation platform for virtual cutting guidance in arthroscopy procedures.

Medtronic

In 2023, Medtronic ranked sixth in the surgical robotics market, a position previously held by Mazor Robotics until Medtronic acquired the company in December 2018. Medtronic leads the robotic-assisted spinal surgery market and is the third-largest in robotic neurosurgery. Its product portfolio includes three robotic platforms: Hugo™ RAS, StealthAutoguide™, and the Mazor X™ Robotic Guidance System.

The Hugo™ Robotic-Assisted Surgery (RAS) system stands out with its cutting-edge features and capabilities designed to enhance surgical precision and efficiency:

Wristed Instruments and 3D Visualization: These components are integral to the system, providing surgeons with enhanced dexterity and a comprehensive view during procedures.
Cloud-Based Integration: The system incorporates Medtronic’s Touch Surgery Enterprise, a cloud-based solution for surgical video capture and management, facilitating seamless data handling and review.
Versatile Multi-Quadrant Platform: Hugo™ is engineered to perform a wide range of soft tissue procedures, making it a versatile tool in the operating room.
Surgeon-Centric Design: The open console and modular design cater to surgeon preferences, ensuring a user-friendly experience that adapts to varied surgical styles.
Connected Digital Ecosystem: By leveraging a connected digital ecosystem and data-enabled insights, Hugo™aims to advance robotic surgery’s reach and effectiveness worldwide.

Medtronic’s approach combines its leading position in minimally invasive surgery with a robust digital infrastructure, aiming to drive growth and innovation in the robotic surgery arena.

Accuray

In 2023, Accuray ranked seventh in the surgical robotics market. The company’s CyberKnife® robotic radiosurgery system, developed in partnership with KUKA AG, uses image guidance and robotics to deliver precise, high-energy radiation to tumors. It is a fully robotic stereotactic radiosurgery and body radiation therapy system for treating various cancers. The system allows treatment in one to five sessions, reducing risks compared to conventional methods, and is FDA-approved for treating tumors throughout the body.

Globus Medical

In 2023, Globus Medical ranked eighth in the surgical robotics market. The company markets the ExcelsiusGPS® robotic guidance system, designed for orthopedic and neurosurgical spine procedures. Acquired in 2014 from Excelsius Surgical and FDA-approved in 2017, ExcelsiusGPS® is compatible with Globus Medical’s implants and instruments.

Additional Competitors

Other notable competitors in the surgical robotics market in the U.S. included, but were not limited to, Asensus Surgical, Brainlab, Catheter Precision, Corin Group, IMRIS, Medrobotics, Renishaw, Siemens Healthineers, Stereotaxis, Synaptive Medical, THINK Surgical, Moon Surgical, Noah Medical, Distalmotion, CRM Surgical, Virtual Incision, and etc.

Capabilities of the Galaxy System for Bronchoscopy

Noah Medical’s Galaxy surgical robotic system offers cutting-edge capabilities specifically designed for robotic-assisted bronchoscopy. This advanced system enhances both diagnostic and therapeutic procedures within patient airways by providing superior bronchoscopic visualization and access.

Features include:

Advanced Imaging Technologies: The system is equipped with state-of-the-art imaging that enables real-time location updates, particularly useful for identifying potentially cancerous lesions.
Enhanced Tool-in-Lesion Accuracy: The precision of the system aids in improving the accuracy of tool placement and boosting the diagnostic yield, ensuring more reliable results in detecting issues.
Integrated Tomosynthesis (TiLT Technology): This proprietary feature provides augmented fluoroscopy, offering continuous vision during procedures. It utilizes a single-use disposable bronchoscope, enhancing safety and sanitation.
Compact Design: The system boasts a small, easy-to-integrate footprint, making it suitable for a variety of bronchoscopy suites without requiring extensive space modifications.

The combination of these features allows the Galaxy system to deliver precise, efficient, and safe bronchoscopic procedures, making it a valuable asset for medical professionals.

Understanding the Difference in Moon Surgical’s Maestro System

Moon Surgical’s Maestro system sets itself apart from conventional surgical robots by serving as an assistant rather than a surgeon substitute. Traditional surgical robots often operate under the direct control of a surgeon, executing precise movements to perform surgical tasks. In contrast, Maestro enhances the surgeon’s capabilities without taking over the procedure.

Key Features of Maestro:

Integration and Adaptability: Unlike many conventional systems that require significant adjustments to existing clinical setups, the Maestro is designed to fit seamlessly into current workflows. This adaptability minimizes disruptions while maximizing efficiency.
Enhanced Operating Room Dynamics: Maestro not only improves precision but also boosts overall efficiency in the operating room. By supporting alternative labor models, it optimizes the team dynamics, allowing for a more streamlined surgical process.
Additional Instrument Control: One of Maestro’s standout features is its dual-arm assistance, granting surgeons the ability to manipulate two extra instruments simultaneously. This capability affords unparalleled access and visibility, ensuring tissues are accessed with greater precision throughout the operation.

In essence, the Maestro system provides an elevated version of traditional laparoscopy, enhancing precision and control, while complementing the surgeon’s expertise.

How Is the Dexter Surgical Robotics System Being Integrated into Clinical Practice?

Distalmotion’s innovative surgical robotics system is making waves in clinical settings due to its seamless integration capabilities. Here’s how:

No Need for Extra Infrastructure: Unlike many complex medical technologies, this system doesn’t require costly infrastructure changes, making it a practical choice for facilities of various sizes.
Universal Compatibility: It’s designed to fit effortlessly into diverse clinical environments. Whether in a small clinic or a bustling hospital, the system adapts to existing setups, ensuring a smooth transition to robotic-assisted procedures.
Mobility Across Departments: A standout feature is its mobility. The system can be easily moved and shared among different departments. This flexibility allows institutions to utilize the technology in multiple surgical areas without the need for redundant purchases.
Expanding Robotic Programs: By facilitating this cross-departmental use, healthcare providers can effectively scale their robotic surgery programs across multiple surgical disciplines. This expansion enhances patient care by incorporating advanced technology in a wider array of procedures.

The system’s integration into clinical practice is transforming surgical care by enhancing efficiency and broadening the availability of robotic-assisted surgeries.

How is CMR Surgical Expanding its Operations and Product Offerings?

Leadership and Team Expansion

The company has bolstered its leadership by appointing experienced industry executives. Notably, they’ve brought in a new CEO with extensive industry experience, as well as a chief commercialization officer with a strong background in healthcare.

Product Development

A key focus for CMR Surgical is the advancement of their surgical robotic system. This includes developing a next-generation system and introducing new products to the line-up, ensuring they remain at the forefront of surgical technology.

Commercialization Strategy

CMR Surgical is reorganizing its operations to better commercialize its existing offerings. This involves streamlining processes and strategically hiring veteran talent to spearhead these efforts.

Strategic Collaborations

The company is fostering targeted collaborations with established players in the healthcare industry. These partnerships are designed to enhance surgical solutions that address the unique needs of patients.

Infrastructure Expansion

To support its growing operations, CMR Surgical is opening a new manufacturing facility spread over approximately 75,000 square feet in the U.K. This expansion will bolster their production capabilities and facilitate further growth.

Financial Growth

CMR Surgical has achieved significant financial milestones, surpassing its fundraising targets with a recent substantial investment round. This financial boost will support its growth initiatives and ongoing innovations.

Through these comprehensive strategies, CMR Surgical is positioning itself as a leader in the surgical robotics space.

Innovative Advancements by Stereotaxis in Endovascular Intervention

Stereotaxis is revolutionizing the field of minimally invasive endovascular intervention through cutting-edge robotic solutions. At the forefront of their innovations is the integration of magnetic technology within the surgical robotics arena, enhancing precision and patient outcomes.

Pioneering Robotic Systems

Genesis RMN System: This system leverages advanced magnetic robotics to conduct minimally invasive procedures, offering unparalleled control and precision.
Vdrive Robotic Navigation System: Enhancing navigational capabilities, this system supports the efficient positioning of diagnostic and therapeutic devices during procedures.
Niobe Robotic Magnetic Navigation System: Utilizes magnetic guidance to perform intricate interventions with exceptional accuracy and safety.

Breakthrough in Cardiac Ablation

Among their latest achievements, Stereotaxis has introduced the Magnetic Interventional Ablation Catheter (MAGiC). This catheter is uniquely robotically navigated and specifically designed to perform minimally invasive cardiac ablations. The initial successful procedures using MAGiC were completed at Vilnius University Hospital Santaros Klinikos, marking a significant milestone in cardiac care.

Collaborating for Enhanced Heart Mapping

In a strategic move to improve procedural outcomes, Stereotaxis has partnered with Abbott. This partnership integrates Abbott’s advanced 3D heart mapping technology, the EnSite X EP system, with Stereotaxis’ magnetic navigation platforms. This collaboration has already seen the successful execution of surgeries, showcasing the enhanced capabilities brought by this innovative pairing.

Through these pioneering technologies, Stereotaxis is setting new standards in the sphere of endovascular interventions, focusing on maximizing the efficacy and safety of minimally invasive procedures worldwide.

Recent Regulatory Approvals in Surgical Robotics

Several surgical robotics companies have recently achieved significant regulatory milestones.

Johnson & Johnson: Their Monarch platform and bronchoscope have received regulatory approval in China. This marks the company’s first robot-assisted technology to be approved in that market.
Moon Surgical: In October 2023, Moon Surgical launched its initial U.S. Clinical cases with the Maestro system in Jacksonville, Florida. The company has also achieved FDA 510(k) clearance and CE mark certification for this innovative technology, further validating its safety and effectiveness.
Noah Medical: The Galaxy surgical robotic system, known for its application in robotic-assisted bronchoscopy, has been celebrated for its 500th use in the United States. This system is equipped with proprietary TiLT Technology, which enhances procedure precision through augmented fluoroscopy and integrates seamlessly with existing bronchoscopy suites.

These advancements reflect the rapidly evolving landscape of surgical robotics, highlighting how companies are expanding their reach and improving medical technology through regulatory successes.

Further Information on the Top Surgical Robotics Companies in the U.S.

More on the top robotic surgery companies in the U.S. can be found in a series of reports published by iData Research entitled the US Market Report Suite for Surgical Navigation and Robotic Systems.

FREE Sample Report